2025-04-04 05:54:25
Latest Post
Sai Life Sciences sets up Peptide Research Center in India
Netweb Technologies Ltd receives PLI Incentive Under IT Hardware Scheme 2.0
BHEL signs contract for ± 800 kV, 6000 MW Bhadla-Fatehpur LCC HVDC Terminal Station along with AC Transmission at Bhadla and Fatehpur
DEE Development Engineers Limited receives order worth approx. Rs. 55 crores- SURATWWALA BUSINESS GROUP Ltd purchases new commercial office space
Stock Report
Lupin's Namuscla® is recommended by NICE for treatment of symptomatic myotonia in adults with non-dystrophic myotonic disorders
Posted On : 2021-11-05 12:07:24( TIMEZONE : IST )
Global pharma major Lupin has announced that the National Institute for Health and Care Excellence (NICE) has issued the Final Appraisal Determination (FAD) recommending the routine funding of Namuscla (mexiletine) in England and Wales. NICE recommends Namuscla (mexiletine) within its marketing authorisation, as an option for treating the symptoms of myotonia in adults with non-dystrophic myotonic disorders. Lupin has agreed a confidential patient access scheme with NHS England (NHSE).
NDM is a group of rare genetic neuromuscular disorders caused by mutations in sodium or chloride ion channels, affecting approximately 400 patients in England. Clinically, NDM manifests with myotonia, a muscle stiffness which makes it difficult to perform daily activities. Myotonia can severely affect different parts of the body with pain, weakness and fatigue being the main symptoms, among others, that accompany the disease.
Namuscla is licensed in the European Union and the UK for the symptomatic treatment of myotonia in adults with NDM.
"We are delighted that NDM patients in England and Wales will be able to access Namuscla. We are grateful to patients, their caregivers and all the healthcare professionals involved in the NICE process. The decision by NICE is a significant step forward for patients with rare disease as well as for repurposing medicines," said Ben Ellis, General Manager of Lupin Healthcare UK. "Lupin's transformational journey into specialty disease areas continues, with future investments planned for neuromuscular diseases, to meet unmet patient need."
Lupin provided comprehensive data to support the NICE submission, demonstrating the efficacy and longterm safety of Namuscla and the significant improvements in the quality of life for NDM patients. Supporting evidence included three randomised controlled studies 4-6 and two retrospective long-term studies.
Shares of Lupin Limited was last trading in BSE at Rs. 933.95 as compared to the previous close of Rs. 934.75. The total number of shares traded during the day was 4615 in over 352 trades.
The stock hit an intraday high of Rs. 941.50 and intraday low of 932.30. The net turnover during the day was Rs. 4317676.00.
